A new study now shows that psychedelic drugs are not the worst thing if used wisely. According to a team of researchers from the University of British Columbia, they have huge medical potential, as they can help people who are suffering from various mental disorders, including depression, addiction and posttraumatic stress disorder (PTSD).
Drugs such as LSD, magic mushrooms or ecstasy can have a therapeutic effect on the person who suffers from mental disorders. For instance, Ecstasy can help people suffering from PTSD, while mushrooms can help reduce the feelings of anxiety (especially end-of-life anxiety) and depression. Other drugs, such as LSD can help relieve many types of anxieties.
According to Mark Hayden, who is the board director of the Multidisciplinary Association of Psychedelic Studies Canada, all the participants in the study showed improvements after taking such drugs.
Thus, about 100 people suffering from PTSD were treated with MDMA, that also goes by the name of “ecstasy for Molly”. These people also underwent intensive psychotherapy. “A dramatic improvement has been noted in all participants,” said Mark Hayden.
Some of the participants were given a standardized dose of MDMA on three occasions. The administration of the drug was carried out in front of a therapist. The other group took a placebo drug at first. After two months, the latter group were also offered MDMA in the same doses.
“It does help people to understand themselves. The permeability between the conscious and unconscious mind is increased when people take psychedelics,” said Hayden.
When the participants’ progress was assessed, the researchers saw that the drug had helped them put an end to their disturbing and aggressive thoughts up to a great extent.
Posttraumatic stress disorder is not easy to deal with and it can be destructive to the person who suffers from it. This is why further research into such treatment can prove useful for them in the long run.
The lead study author, Dr. Evan Wood, said that the study might face a lot of criticism, but its goal is to break the taboo and start looking at the possibilities that have not yet been explored.
The results of the study were published in the Canadian Medical Association Journal on Tuesday, September 8.
Image Source: drugware